Cian Healthcare Ltd — Results, 19-06-2025: Result

Cian Healthcare Limited, currently under Corporate Insolvency Resolution Process (CIRP), has announced a board meeting regarding the financial results for the quarter and half-year ending March 31, 2025. The standalone results have been finalized and approved by the Committee of Creditors, but consolidated results remain pending due to unavailable data from its wholly owned subsidiary, Dr. Smiths Biotech Private Limited, which is also under CIRP. The standalone audited financials show a net loss of ₹19.65 Cr (adjusted loss ₹29.36 Cr) with total assets at ₹142.67 Cr, but the statutory auditors issued a disclaimer of opinion citing significant uncertainties, lack of audit evidence, unresolved claims, and potential adjustments related to inventory valuation, loans, and balances with authorities. The company continues operations but faces material uncertainty around its ability to continue as a going concern pending the approval of a resolution plan by the NCLT, which is currently under process. Exceptional items include batch closure costs of ₹11.09 Cr and sundry balances written off ₹1.08 Cr. Investor complaints stand resolved.